Biogen Mulls Tofersen's Future after Drug Misses Phase III Trial's Primary Endpoint in ALS
Biogen said that it is evaluating next steps for tofersen (BIIB067) after acknowledging that the antisense drug missed its primary endpoint in a Phase III trial in people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).
Source: genengnews.com